Stock Analysis on Net

Edwards Lifesciences Corp. (NYSE:EW)

$22.49

This company has been moved to the archive! The financial data has not been updated since February 14, 2022.

Analysis of Revenues

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Revenues as Reported

Edwards Lifesciences Corp., income statement, revenues

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
Transcatheter Aortic Valve Replacement
Transcatheter Mitral and Tricuspid Therapies
Surgical Structural Heart
Critical Care
Net sales

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).


Overall Revenue Growth
The total net sales demonstrate a consistent upward trend over the five-year period, increasing from $3,435,300 thousand in 2017 to $5,232,500 thousand in 2021. This represents a substantial increase in overall revenue, indicating positive business expansion.
Transcatheter Aortic Valve Replacement (TAVR)
This segment shows steady growth every year, starting from $2,023,800 thousand in 2017 and reaching $3,422,500 thousand in 2021. The growth is particularly notable in the last two years, suggesting increased market adoption or product demand associated with TAVR technology.
Transcatheter Mitral and Tricuspid Therapies
This category started at a very low base of $3,400 thousand in 2017 and experienced rapid growth to $86,000 thousand by 2021. The sharp increase, especially after 2018, indicates this may be a new or rapidly developing segment with significant expansion during the period.
Surgical Structural Heart
The Surgical Structural Heart segment exhibits some fluctuations. It decreased slightly from $807,100 thousand in 2017 to $761,600 thousand in 2018, then rose to $841,700 thousand in 2019, followed by another dip in 2020 to $761,800 thousand. By 2021, it increased again to $889,100 thousand. This pattern suggests market volatility or changing demand in this segment but with a positive recovery by the end of the period.
Critical Care
Critical Care revenues show steady but modest growth over the years, increasing from $601,000 thousand in 2017 to $834,900 thousand in 2021. The growth is fairly consistent with a minor decline from 2019 to 2020 but a rebound in 2021, pointing to stable demand in this segment.